Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioAge, obesity
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.
Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
BioAge prices $198M IPO, validating pivot to obesity drug research
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO
Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.
6h
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...
4d
on MSN
BioAge, BKV shares end their first trading day flat after earlier gains
Obesity-drug developer BioAge held on to a slim gain after rising more than 20%, while Texas-based Barnett Shale driller BKV ...
FierceBiotech
4d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
5d
BioAge seeks nearly $200 million in initial public offering
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
2d
U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up
Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Four IPOs and two SPACs submitted ...
5d
on MSN
Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United ...
3d
Ryan Reynolds's MNTN Explores Going Public, as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...
4d
on MSN
BioAge posts double-digit percentage gain after IPO; natural-gas producer BKV rises in debut
Obesity-drug developer BioAge jumps nearly 30% while Texas-based Barnett Shale driller BKV posts smaller gain.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
IPO
Initial public offering
BKV
Feedback